

## Notes

ADDITIONAL COCHINMICINS FROM  
*A Microbispora* sp.Y. K. TONY LAM, DEBORAH L. ZINK,  
DAVID L. WILLIAMS, Jr.<sup>†</sup>  
and BRUCE W. BURGESSMerck Research Laboratories,  
Rahway, New Jersey 07065, U.S.A., and  
<sup>†</sup>West Point, Pennsylvania 19486, U.S.A.

(Received for publication June 15, 1992)


Recently, we have described the discovery of cochinmicins I (1), II (2) and III (3) (Fig. 1) as endothelin antagonists from the fermentation of a *Microbispora* sp., ATCC 55140<sup>1,2</sup>. Subsequently, in working with a directly scaled up fermentation, we found two additional components, IV (4) and V (5), in sufficient amounts for characterization. In this paper, we will present the isolation as well as physico-chemical and biochemical characterization of these two new metabolites.

In the present fermentation, the seed nutrient and production media employed were the same as those reported previously<sup>1</sup>. A two stage seed method of 4 and then 0.8% inoculum was used with incubation at 28°C and 220 rpm for 96 and 72 hours, respectively. Production of cochinmicins was carried out in 75-liter stainless steel fermenters containing 50 liters of the production medium. An inoculum of 3.0% was used. The fermentation was carried out at 25°C and pH 6.4~7.3, under an aeration of 15 liters/minute and a stirrer speed of 400~500 rpm. Production of 2 was followed by HPLC analysis. A time course of this fermentation in a 75-liter fermenter is shown in Fig. 2. Production of 2 starts during log phase and reaches a maximum at 9 to 10 days of fermentation followed by a sharp decline to 40% of the peak level in 24 hours.

The whole broth from two fermenters (100 liters) was immediately extracted with methylethyl ketone (MEK, 2 × 100 liters). Flash evaporation of the MEK layer to dryness under reduced pressure at <40°C gave 245 g of crude extract. This crude extract was mixed with CH<sub>2</sub>Cl<sub>2</sub> (850 ml) and adsorbed on to an open column of 2.5 kg Silica gel 60 (E. Merck, 0.2~0.5 mm particle size) in the same solvent. Stepwise gradient elution with 7, 25 and 24 liters of 0, 5 and 10% MeOH - CH<sub>2</sub>Cl<sub>2</sub>,

respectively, afforded 32.6 g of cochinmicin enriched fraction in the 10% MeOH - CH<sub>2</sub>Cl<sub>2</sub> effluent. In this exercise, the enriched fraction was purified as two

Fig. 1. The structures of cochinmicins I~V (1~5).



Cochinmicins	X	R	*
1	I	H	CH <sub>3</sub>
2	II	Cl	CH <sub>3</sub>
3	III	Cl	CH <sub>3</sub>
4	IV	Cl	CH <sub>2</sub> OH
5	V	H	CH <sub>3</sub>

Fig. 2. Time course of production of cochinmicin II (2) in a 75-liter fermenter.




Table 1. Physico-chemical and biochemical characteristics of **4** and **5**.

	4	5
Molecular formula	C <sub>46</sub> H <sub>46</sub> N <sub>7</sub> O <sub>13</sub> Cl	C <sub>46</sub> H <sub>47</sub> N <sub>7</sub> O <sub>12</sub>
HRFAB-MS ((M+H) <sup>+</sup> m/z)		
Found:	940.2921	890.3360
Calcd:	940.2920	890.3361
[ $\alpha$ ] <sub>D</sub> <sup>23</sup>	+30.0° (c 0.1 in MeOH)	+20.0° (c 0.1 in MeOH)
UV $\lambda_{\max}^{\text{MeOH}}$ nm (E <sub>1%</sub> <sup>1cm</sup> )	214 (485), 229 (sh, 240), 274 (234)	214 (489), 230 (sh, 237), 270 (224)
FT-IR (ZnSe) $\nu_{\max}$ cm <sup>-1</sup>	3309, 1738, 1661, 1607, 1525	3302, 1739, 1661, 1555, 1516
HPLC <sup>a</sup> Rt (minutes)	4.4	3.3
[ <sup>125</sup> I]Endothelin binding:		
IC <sub>50</sub> ( $\mu$ M)		
Cow aorta	3	90
Rat hippocampus	2	25

sh: Shoulder.

<sup>a</sup> Whatman Partisil 5 ODS-3, 4.6 × 100 mm; MeOH - H<sub>2</sub>O (45 : 55); flow rate, 1 ml/minute; 40°C; UV monitor at 215 nm.

injections on a Separations Technology C-18 column (7.6 × 91 cm, 0.02 mm particle size) using 55% MeOH (aq) as the mobile phase for elution at 200 ml/minute and room temperature, monitoring the effluent at 270 nm. This step afforded, in order of elution, 0.66 g of enriched **5**, 0.19 g of homogeneous **4**, 16 g of **2** and 1.47 g of **3** at elution volumes of 9.2~11.5, 17.4~19.2, 22.5~30.7 and 39.0~47.7 liters, respectively. Thus, using the present procedure, **2**, **3** and **4** can be isolated in two chromatographic steps from whole broth.

The above fraction enriched in **5** was purified as one sample on a Whatman Partisil 10 ODS-3 column (2.21 × 50 cm). Elution was performed with 45% MeOH (aq) at 15 ml/minute and room temperature. The effluent was monitored at 215 nm. Homogeneous **5** (0.49 g) was recovered from elution volumes of 480~675 ml.

Physico-chemical analyses were performed using methods previously described. The physico-chemical characteristics of **4** and **5** are summarized in Table 1.

Comparison of <sup>1</sup>H and <sup>13</sup>C NMR data (DMSO-*d*<sub>6</sub> and CD<sub>3</sub>OD) with those reported for **1**, **2** and **3** suggested that **4** and **5** are new members of the cochlinic family. Of importance, stereochemically both **4** and **5** are **2**-like rather than **3**-like. In addition, both **4** and **5**, like **2**, are dextrorotatory. Structures of the new members were determined by methods described previously.

Using the  $\alpha$ -methylbenzyl isothiocyanate method described earlier<sup>2)</sup>, the total hydrolysate of **4** showed the presence of D-Ser, D-*allo*-Thr, L-dihydroxyphenylglycine, D-dihydroxyphenylglycine, L-Phe and D-Phe. D-Ala was absent. A D-Ser replacement of D-Ala accounted for an increase of 16 mass units

of **4** from **2**. **4** possesses <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 300 MHz) chemical shifts at  $\delta$  1.11 (d, *J* = 6.5 Hz, 3H, D-*allo*-Thr H<sub>γ</sub>), 3.71 (brs, 2H, D-Ser H<sub>β</sub>), 4.02 (dd, *J* = 5.5, 4.5 Hz, 1H, D-Ser H<sub>α</sub>), and pyrrole protons at 6.03 (d, *J* = 4 Hz, 1H), 6.90 (d, *J* = 4 Hz, 1H) and 12.21 (brs, NH) ppm. The <sup>13</sup>C NMR spectra of **4** (DMSO-*d*<sub>6</sub>, 75 MHz, coupled, decoupled and APT) showed a quartet at  $\delta$  16.6, three triplets at  $\delta$  37.1, 38.2 and 60.4, twenty four doublets at  $\delta$  53.7, 54.9, 55.7, 56.4, 56.7, 58.4, 70.7, 102.0, 102.2, 106.5 (2 ×), 107.1 (2 ×), 111.7, 126.26, 126.35, 128.0 (2 ×), 128.2 (2 ×), 129.1 (2 ×) and 129.2 (2 ×), and seventeen singlets at  $\delta$  117.2, 125.8, 136.9, 137.8, 138.4, 139.4, 158.1 (2 ×), 158.2 (2 ×), 159.1, 168.3, 168.5, 169.0, 170.0, 171.4, 171.5 ppm. These data for **4** are consistent with assigning it as [D-Ser<sup>5</sup>]**2**.

**5** is identical (HPLC retention time, <sup>1</sup>H and <sup>13</sup>C NMR, UV, IR and MS) to semisynthetic deschloro-**2**, obtained from catalytic hydrogenation of **2** using an analogous method reported for the conversion of **3** to **1**<sup>1)</sup>. The <sup>1</sup>H NMR spectrum (DMSO-*d*<sub>6</sub>, 300 MHz) of **5** revealed chemical shifts for pyrrole protons at  $\delta$  6.06 (dd, 1H, *J* = 2.4, 6 Hz), 6.82 (m, 1H), 6.89 (m, 1H), and  $\delta$  11.40 (br d, *J* = 1.8 Hz, NH) ppm. The <sup>13</sup>C NMR spectra of **5** (DMSO-*d*<sub>6</sub>, 75 MHz, coupled, decoupled and APT) showed quartets at  $\delta$  16.6 and 16.9, two triplets at  $\delta$  36.7 and 38.0, twenty six doublets at  $\delta$  51.9, 53.9, 55.0, 55.8, 56.1, 56.2, 70.7, 101.9, 102.1, 106.6 (2 ×), 106.9 (2 ×), 108.6, 110.7, 121.5, 126.2, 126.3, 128.0 (2 ×), 128.2 (2 ×), 129.1 (2 ×) and 129.2 (2 ×), and sixteen singlets at  $\delta$  125.8, 137.0, 138.0, 138.3, 139.7, 158.0 (2 ×), 158.2 (2 ×), 160.2, 168.4, 168.7, 168.9, 171.2, 171.7 and 172.3 ppm.

The [<sup>125</sup>I]endothelin binding data for **4** and **5**,

obtained by methods described previously, is also summarized in Table 1. **4** showed comparable **2**-like affinities, which are significantly weaker than **1** and **3** for both ET-A and ET-B sites. **5** is the least active member. These observations further corroborate with the notion that the *S* stereochemistry at the carbon marked \* (*i.e.* L-dihydroxyphenylglycine) and chloro substitution at the 5-position in the pyrrole is deleterious to inhibiting endothelin binding.

At a 20 µg/disc level, **4** and **5** do not exhibit any antimicrobial activity against *Bacillus subtilis* (ATCC 6633), *Staphylococcus aureus* (ATCC 6538P), *Micrococcus luteus* (ATCC 9341), *Escherichia coli* (ATCC 9637), *Proteus vulgaris* (ATCC 21100), *Pseudomonas aeruginosa* (ATCC 25619), *Cochliobolus miyabeanus* (ATCC 11608) and *Acholeplasma laidlawii* (ATCC 23206).

#### Acknowledgments

The authors would like to thank Ms. N. W. LEE for antimicrobial tests.

#### References

- 1) LAM, Y. K. T.; D. L. WILLIAMS, JR., J. M. SIGMUND, M. SANCHEZ, O. GENILLOU, Y. L. KONG, S. STEVENS-MILES, L. HUANG & G. M. GARRITY: Cochlinmicins, novel and potent cyclodepsipeptide endothelin antagonists from a *Microbispora* sp. I. Production, isolation, and characterization. *J. Antibiotics* 45: 1709~1716, 1992
- 2) ZINK, D.; O. HENSENS, Y. K. T. LAM, R. REAMER & J. M. LIESCH: Cochlinmicins, novel and potent cyclodepsipeptide endothelin antagonists from a *Microbispora* sp. II. Structure determination. *J. Antibiotics* 45: 1717~1722, 1992